PL2107069T3 - Nowe pochodne insuliny - Google Patents

Nowe pochodne insuliny

Info

Publication number
PL2107069T3
PL2107069T3 PL09165072T PL09165072T PL2107069T3 PL 2107069 T3 PL2107069 T3 PL 2107069T3 PL 09165072 T PL09165072 T PL 09165072T PL 09165072 T PL09165072 T PL 09165072T PL 2107069 T3 PL2107069 T3 PL 2107069T3
Authority
PL
Poland
Prior art keywords
insulin derivatives
novel insulin
novel
derivatives
insulin
Prior art date
Application number
PL09165072T
Other languages
English (en)
Polish (pl)
Inventor
Ib Jonassen
Thomas Hoeg-Jensen
Svend Havelund
Ulla Ribel-Madsen
Tagmose Tina Moller
Peter Madsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of PL2107069T3 publication Critical patent/PL2107069T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL09165072T 2003-08-05 2004-07-22 Nowe pochodne insuliny PL2107069T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200301129 2003-08-05
US49545103P 2003-08-14 2003-08-14
EP04739008A EP1660531A2 (en) 2003-08-05 2004-07-22 Novel insulin derivatives
EP09165072A EP2107069B1 (en) 2003-08-05 2004-07-22 Novel insulin derivatives

Publications (1)

Publication Number Publication Date
PL2107069T3 true PL2107069T3 (pl) 2013-06-28

Family

ID=34117520

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09165072T PL2107069T3 (pl) 2003-08-05 2004-07-22 Nowe pochodne insuliny

Country Status (18)

Country Link
US (3) US7615532B2 (OSRAM)
EP (3) EP2107069B1 (OSRAM)
JP (1) JP4463814B2 (OSRAM)
KR (1) KR101159559B1 (OSRAM)
AU (2) AU2004261353B2 (OSRAM)
BE (2) BE2013C035I2 (OSRAM)
BR (1) BRPI0413276B8 (OSRAM)
CA (1) CA2531988C (OSRAM)
CY (5) CY1113850T1 (OSRAM)
FR (2) FR13C0035I2 (OSRAM)
HU (1) HUS1300033I1 (OSRAM)
IL (1) IL172980A (OSRAM)
LU (2) LU92213I2 (OSRAM)
MX (1) MXPA06001283A (OSRAM)
NO (5) NO340925B1 (OSRAM)
PL (1) PL2107069T3 (OSRAM)
RU (1) RU2518460C2 (OSRAM)
WO (1) WO2005012347A2 (OSRAM)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004261319B2 (en) * 2003-07-25 2010-12-23 Conjuchem Biotechnologies Inc. Long lasting insulin derivatives and methods thereof
EP2107069B1 (en) 2003-08-05 2013-01-16 Novo Nordisk A/S Novel insulin derivatives
EP1846447B1 (en) 2005-02-02 2013-08-21 Novo Nordisk A/S Insulin derivatives
EP2256130B1 (en) 2005-02-02 2013-09-25 Novo Nordisk A/S Novel insulin derivatives
EP2505593A1 (en) * 2005-12-28 2012-10-03 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
DE602007009496D1 (de) 2006-02-27 2010-11-11 Novo Nordisk As Insulinderivate
WO2007104736A2 (en) * 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
EP2015722B1 (en) 2006-04-28 2016-11-16 Avent, Inc. Antimicrobial site dressings
CN101437849B (zh) * 2006-05-09 2015-09-30 诺沃-诺迪斯克有限公司 胰岛素衍生物
MX2008014061A (es) * 2006-05-09 2008-11-14 Novo Nordisk As Derivado de insulina.
EP2024390B1 (en) * 2006-05-09 2015-08-19 Novo Nordisk A/S Insulin derivative
JP5097900B2 (ja) * 2006-06-27 2012-12-12 独立行政法人物質・材料研究機構 有機酸又はこれらの誘導体の活性エステル体の製造方法
JP5550338B2 (ja) 2006-07-31 2014-07-16 ノボ・ノルデイスク・エー/エス ペグ化持続型インスリン
EP2074141B1 (en) 2006-09-22 2016-08-10 Novo Nordisk A/S Protease resistant insulin analogues
WO2008132224A2 (en) 2007-04-30 2008-11-06 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
MX2009012789A (es) * 2007-06-01 2009-12-10 Novo Nordisk As Composiciones farmaceuticas no acuosas estables.
JP2011504871A (ja) 2007-06-01 2011-02-17 ノボ・ノルデイスク・エー/エス 固体又は半固体担体中にペプチド薬剤を含む自然に分散可能なプレコンセントレイト
CN101677947B (zh) 2007-06-13 2013-07-17 诺沃-诺迪斯克有限公司 包含胰岛素衍生物的药物制剂
US9150633B2 (en) * 2007-08-15 2015-10-06 Novo Nordisk A/S Insulin analogues with an acyl and alkylene glycol moiety
EP2178910B1 (en) 2007-08-15 2014-10-08 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
CN101157725B (zh) * 2007-10-24 2012-07-25 中国药科大学 人胰岛素类似物的制备方法及用途
CN101932601B (zh) * 2007-11-08 2016-08-03 诺沃-诺迪斯克有限公司 胰岛素衍生物
CA2705821A1 (en) 2007-11-16 2009-05-22 Novo Nordisk A/S Pharmaceutical compositions containing insulin and an insulinotropic peptide
CN101970477B (zh) 2008-03-14 2014-12-31 诺沃-诺迪斯克有限公司 蛋白酶稳定的胰岛素类似物
PT2910570T (pt) 2008-03-18 2017-01-24 Novo Nordisk As Análogos de insulina acilados, estabilizados contra proteases
US8637647B2 (en) 2008-09-12 2014-01-28 Novo Nordisk A/S Method of acylating a peptide or protein
AU2009309623B9 (en) * 2008-10-30 2014-10-02 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
JP5599822B2 (ja) 2009-01-23 2014-10-01 ノヴォ ノルディスク アー/エス アルブミンバインダーa−b−c−d−e−を有するfgf21誘導体及びそれらの使用
EP2493919A1 (en) 2009-10-30 2012-09-05 Novo Nordisk A/S Derivatives of cgrp
BR112012016853A2 (pt) * 2010-01-12 2017-10-17 Novo Nordisk As "composições farmacêuticas para administração oral de peptídeos de insulina".
CN102812039B (zh) 2010-02-16 2016-01-20 诺沃—诺迪斯克有限公司 缀合蛋白质
US20130012684A1 (en) 2010-02-16 2013-01-10 Novo Nordisk A/S Purification Method
US20130143803A1 (en) 2010-05-10 2013-06-06 Novo Nordisk A/S Process for the Preparation of Insulin-Zinc Complexes
EP2576593A4 (en) 2010-05-25 2014-07-09 Syngene Ltd PROCESS FOR THE SYNTHESIS OF DICARBA BRIDGES IN PEPTIDES
KR20130036290A (ko) 2010-06-23 2013-04-11 노보 노르디스크 에이/에스 추가 이황화 결합을 함유하는 인슐린 유도체
EP2585484A1 (en) 2010-06-23 2013-05-01 Novo Nordisk A/S Insulin analogues containing additional disulfide bonds
JP6013330B2 (ja) 2010-06-23 2016-10-25 ノヴォ ノルディスク アー/エス 追加のジスルフィド結合を含有するヒトインスリン
EP2627670A2 (en) 2010-10-15 2013-08-21 Novo Nordisk A/S Novel n-terminally modified insulin derivatives
RU2013123515A (ru) * 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
EP2632478B1 (en) 2010-10-27 2019-07-24 Novo Nordisk A/S Treating diabetes melitus using insulin injections administered with varying injection intervals
EP2651432A1 (en) 2010-12-14 2013-10-23 Novo Nordisk A/S Fast-acting insulin in combination with long-acting insulin
EP2675470A1 (en) 2011-02-15 2013-12-25 Novo Nordisk A/S Long-acting il-1 receptor antagonists
CN103596583B (zh) * 2011-03-28 2016-07-27 诺沃—诺迪斯克有限公司 新型胰高血糖素类似物
CN103458873B (zh) 2011-04-14 2016-04-13 诺沃—诺迪斯克有限公司 用于口服肽递送的脂肪酸酰化的氨基酸
JP6058646B2 (ja) 2011-06-15 2017-01-11 ノヴォ ノルディスク アー/エス 多置換インスリン
CA2849673A1 (en) * 2011-09-23 2013-03-28 Novo Nordisk A/S Novel glucagon analogues
AU2012350586B2 (en) * 2011-12-15 2017-02-02 Jiangsu Hengrui Medicine Co., Ltd. Human insulin analogue and acylated derivative thereof
EP2794648A1 (en) 2011-12-21 2014-10-29 Novo Nordisk A/S N-terminally modified insulin derivatives
BR112014025132A2 (pt) 2012-04-11 2017-07-11 Novo Nordisk As formulações de insulina
US20160031962A1 (en) * 2012-04-20 2016-02-04 Kleomenis K. Barlos Solid phase peptide synthesis of insulin using side chain achored lysine
US9884094B2 (en) 2012-05-01 2018-02-06 Novo Nordisk A/S Method of treating diabetes mellitus
EP2869830B1 (en) 2012-07-09 2016-10-12 Novo Nordisk A/S Novel use of insulin derivatives
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
EP2908846A1 (en) 2012-10-17 2015-08-26 Novo Nordisk A/S Fatty acid acylated d-amino acids for oral peptide delivery
MX362190B (es) 2012-12-21 2019-01-08 Sanofi Sa Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon.
JP6755175B2 (ja) * 2013-03-20 2020-09-16 ノヴォ ノルディスク アー/エス インスリン投薬レジメン
PL2986313T3 (pl) 2013-04-18 2019-12-31 Novo Nordisk A/S Stabilni, dłużej działający współagoniści receptora glp-1/glukagonu do zastosowań medycznych
WO2014177623A1 (en) 2013-04-30 2014-11-06 Novo Nordisk A/S Novel administration regime
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
PT3055325T (pt) 2013-10-07 2018-04-06 Novo Nordisk As Novo derivado de um análogo de insulina
FR3013049B1 (fr) 2013-11-14 2015-11-13 You-Ping Chan Analogue de l'insuline glargine
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽-4(exendin-4)胜肽類似物
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
KR20160114082A (ko) 2014-02-18 2016-10-04 노보 노르디스크 에이/에스 안정한 글루카곤 유사체 및 저혈당증의 치료를 위한 용도
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
JP2017525656A (ja) 2014-06-04 2017-09-07 ノヴォ ノルディスク アー/エス 医療用のglp−1/グルカゴン受容体コアゴニスト
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物
US20180244743A1 (en) 2015-08-25 2018-08-30 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
EP3341401A1 (en) 2015-08-25 2018-07-04 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
US10815287B2 (en) 2016-08-02 2020-10-27 Jiangsu Hengrui Medicine Co., Ltd. Acylated derivative of human insulin or analogue thereof
WO2018096162A1 (en) 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec in cardiovascular conditions
EP3544682A1 (en) 2016-11-28 2019-10-02 Novo Nordisk A/S Insulin degludec for improvement of glycaemic control and reduction of acute and long-term diabetes complications
WO2018096164A1 (en) 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for treating diabetes
PT3554534T (pt) 2016-12-16 2021-11-05 Novo Nordisk As Composições farmacêuticas contendo insulina
JOP20190273A1 (ar) * 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
AU2019218315A1 (en) 2018-02-09 2020-07-09 Jiangsu Hengrui Medicine Co., Ltd. Codon optimized precursor gene and signal peptide gene of human insulin analogue
TWI742377B (zh) 2018-05-24 2021-10-11 大陸商江蘇恒瑞醫藥股份有限公司 一種重組人胰島素或其類似物的前驅物的製備方法
WO2020002428A1 (en) 2018-06-26 2020-01-02 Novo Nordisk A/S System providing dose recommendations for basal insulin titration
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
KR102666154B1 (ko) 2018-08-08 2024-05-20 주식회사 대웅제약 지속형 인슐린 아날로그 및 그 복합체
KR20200080747A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법
KR20200080748A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
TW202434620A (zh) 2019-07-31 2024-09-01 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
US20240239862A1 (en) 2019-12-30 2024-07-18 Gan & Lee Pharmaceuticals Co., Ltd. Insulin Derivative
PE20230832A1 (es) 2020-05-15 2023-05-19 Lilly Co Eli Compuestos de insulina acilada de accion temporal prolongada
CN113773398B (zh) * 2020-06-10 2023-05-23 宁波鲲鹏生物科技有限公司 一种德谷胰岛素衍生物及其应用
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
WO2023084118A1 (en) 2021-11-15 2023-05-19 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
CN118574842A (zh) 2022-01-28 2024-08-30 甘李药业股份有限公司 酰化胰岛素
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid
US20250154220A1 (en) * 2023-11-15 2025-05-15 Ambio, Inc. Insulin analogs for the treatment of human metabolic disorder and disease

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1212679B (de) 1957-08-03 1966-03-17 Novo Terapeutisk Labor As Verfahren zur Herstellung von Insulinloesungen
GB1042194A (en) 1962-04-30 1966-09-14 Olin Mathieson Insulin preparations
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3868358A (en) 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
GB1492997A (en) 1976-07-21 1977-11-23 Nat Res Dev Insulin derivatives
JPS5767548A (en) 1980-10-14 1982-04-24 Shionogi & Co Ltd Insulin analog and its preparation
FI78616C (fi) 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
DE3827533A1 (de) 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
WO1990007522A1 (en) 1988-12-23 1990-07-12 Novo Nordisk A/S Human insulin analogues
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
DK0506792T3 (da) 1989-12-21 1995-10-09 Novo Nordisk As Insulinpræparat, der indeholder nikotinsyre eller nikotinamid
DK45590D0 (OSRAM) 1990-02-21 1990-02-21 Novo Nordisk As
JP3193398B2 (ja) 1991-07-23 2001-07-30 サンデン株式会社 ショ−ケ−ス
RO111990B1 (ro) 1991-12-20 1997-04-30 Novo Nordisk As Preparate farmaceutice, continand un hormon de crestere sau un derivat al acestuia, si procedeu de preparare
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
DE122004000035I2 (de) 1993-09-17 2009-08-06 Novo Nordisk As Acyliertes insulin
US5652216A (en) 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
WO1996010417A1 (en) 1994-10-04 1996-04-11 Novo Nordisk A/S PREPARATIONS CONTAINING AspB28 HUMAN INSULIN AND NICOTINAMIDE
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5830999A (en) 1995-01-26 1998-11-03 Regents Of The University Of California Stabilization of insulin through ligand binding interations
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
AU720966B2 (en) 1995-03-17 2000-06-22 Novo Nordisk A/S Insulin derivatives
MX9800684A (es) 1995-07-27 1998-04-30 Genentech Inc Formulacion de proteinas liofilizadas isotonicas estables.
US6451970B1 (en) * 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
US5898267A (en) * 1996-04-10 1999-04-27 Mcdermott; Kevin Parabolic axial lighting device
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
JP3300368B2 (ja) 1996-07-11 2002-07-08 ノボ ノルディスク アクティーゼルスカブ 選択的アシル化方法
US5905140A (en) 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
EP0821006B1 (de) 1996-07-26 2004-04-21 Aventis Pharma Deutschland GmbH Insulinderivate mit erhöhter Zinkbindung
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
AU6611998A (en) 1997-03-20 1998-10-20 Novo Nordisk A/S Therapeutic powder formulation for pulmonary administration, containing crystalline insulin
AU742591B2 (en) * 1997-03-20 2002-01-10 Novo Nordisk A/S Zinc free insulin crystals for use in pulmonary compositions
EP0969860B1 (en) 1997-03-20 2002-07-17 Novo Nordisk A/S Method for preparation of a therapeutic powder through coprecipitation of insulin and absorption enhancer
US7097845B2 (en) 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
SI0884053T1 (en) 1997-06-13 2003-02-28 Eli Lilly And Company Stable insulin formulations
US20020155994A1 (en) 1997-10-24 2002-10-24 Svend Havelund Aggregates of human insulin derivatives
BR9813111A (pt) 1997-10-24 2000-08-15 Lilly Co Eli Composições de insulina insolúveis
US6451762B1 (en) 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
UA69393C2 (uk) * 1997-10-24 2004-09-15 Ново Нордіск А/С Водорозчинний агрегат похідної інсуліну
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
US6531448B1 (en) 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
DE69924232D1 (de) 1998-01-09 2005-04-21 Novo Nordisk As Stabilisierte insulin-zubereitungen
EP1121144B1 (en) 1998-10-16 2002-06-05 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
DK2130554T3 (da) 1999-02-22 2012-12-03 Univ Connecticut Albuminfrie faktor VIII-præparater
AU4450700A (en) 1999-04-27 2000-11-10 Eli Lilly And Company Insulin crystals for pulmonary administration
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DK1412384T3 (da) 2001-06-28 2008-04-28 Novo Nordisk As Stabil formulering af modificeret GLP-1
EP1545460A4 (en) 2001-12-20 2005-11-16 Lilly Co Eli INSULIN MOLECULE WITH TEMPORARY EFFECT
WO2003075950A1 (en) 2002-03-13 2003-09-18 Novo Nordisk A/S Minimising body weight gain in insulin treatment
EP1506230B1 (en) 2002-05-07 2011-01-19 Novo Nordisk A/S Soluble formulations comprising monomeric insulin and acylated insulin
US20050232899A1 (en) 2002-05-31 2005-10-20 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US20040002451A1 (en) 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
KR100615389B1 (ko) 2002-08-23 2006-08-25 (주)헬릭서 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품
EP1562626B1 (en) 2002-10-29 2007-11-28 ALZA Corporation Stabilized, solid-state polypeptide particles
US20040138099A1 (en) 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
WO2004069259A1 (ja) 2003-02-07 2004-08-19 Ajinomoto Co., Inc. 糖尿病治療剤
BRPI0407680A (pt) 2003-02-19 2006-03-01 Novartis Ag métodos para diagnóstico de cáncer e diminuição de metástase por células cancerosas
AU2004216909A1 (en) 2003-03-04 2004-09-16 The Technology Development Company Ltd. Delivery system for drug and cell therapy
ES2382157T3 (es) 2003-06-25 2012-06-05 Novo Nordisk Health Care Ag Composición líquida de polipépttidos del factor VII
US20050054818A1 (en) 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
EP2107069B1 (en) 2003-08-05 2013-01-16 Novo Nordisk A/S Novel insulin derivatives
PT2107069E (pt) 2003-08-05 2013-04-23 Novo Nordisk As Novos derivados de insulina
CN102872451A (zh) 2003-08-14 2013-01-16 诺和诺德医疗保健公司 因子vii多肽类的含水液体药物组合物
JP5518282B2 (ja) 2003-09-01 2014-06-11 ノヴォ ノルディスク アー/エス 安定なペプチドの製剤
ES2229931B1 (es) 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
EP1687428A1 (en) 2003-11-14 2006-08-09 Novo Nordisk A/S Processes for making acylated insulin
BRPI0418115A (pt) 2003-12-23 2007-04-17 Pharmacia Corp formulação lìquida estável de hormÈnio de crescimento
PL2319500T3 (pl) 2004-03-12 2013-05-31 Biodel Inc Szybko działające kompozycje do dostarczania leku
WO2005117948A1 (en) 2004-06-01 2005-12-15 Ares Trading S.A. Method of stabilizing proteins
ES2349472T3 (es) 2004-08-12 2011-01-03 Schering Corporation Formulación estable de interferón pegilado.
WO2006023665A2 (en) 2004-08-17 2006-03-02 Regeneron Pharmaceuticals, Inc. Il-1 antagonist formulations
WO2006051103A2 (en) 2004-11-12 2006-05-18 Novo Nordisk A/S Stable formulations of peptides
CN101060856B (zh) 2004-11-22 2011-01-19 诺和诺德公司 可溶、稳定的含胰岛素制剂
AU2006206272A1 (en) 2005-01-21 2006-07-27 Alza Corporation Therapeutic peptide formulations for coating microneedles with improved stabitity containing at least one counterion
EP2256130B1 (en) * 2005-02-02 2013-09-25 Novo Nordisk A/S Novel insulin derivatives
EP2505593A1 (en) 2005-12-28 2012-10-03 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
DE602007009496D1 (de) 2006-02-27 2010-11-11 Novo Nordisk As Insulinderivate
WO2007121256A2 (en) 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
MX2008014061A (es) 2006-05-09 2008-11-14 Novo Nordisk As Derivado de insulina.
CN101677947B (zh) 2007-06-13 2013-07-17 诺沃-诺迪斯克有限公司 包含胰岛素衍生物的药物制剂
CA2705821A1 (en) 2007-11-16 2009-05-22 Novo Nordisk A/S Pharmaceutical compositions containing insulin and an insulinotropic peptide
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物

Also Published As

Publication number Publication date
LU92226I2 (fr) 2015-04-29
CY2013027PI2 (el) 2015-11-04
BE2013C035I2 (OSRAM) 2023-12-14
EP2107069B1 (en) 2013-01-16
US8828923B2 (en) 2014-09-09
MXPA06001283A (es) 2006-04-11
BE2013C038I2 (OSRAM) 2023-12-14
NO2018002I2 (no) 2018-08-20
US20100009899A1 (en) 2010-01-14
FR13C0035I1 (OSRAM) 2013-08-09
AU2010200497A1 (en) 2010-03-04
JP4463814B2 (ja) 2010-05-19
EP2264065B1 (en) 2017-03-08
NO20061026L (no) 2006-03-02
US7615532B2 (en) 2009-11-10
CY2013027I2 (el) 2024-09-20
US20140349925A1 (en) 2014-11-27
CY1113850T1 (el) 2015-11-04
CA2531988C (en) 2016-06-28
CY2013027PI1 (el) 2015-11-04
CY2013029PI1 (el) 2015-11-04
IL172980A0 (en) 2006-06-11
NO2024003I1 (no) 2024-01-16
AU2010200497B2 (en) 2014-10-23
HUS1300033I1 (hu) 2016-08-29
CY2013027I1 (el) 2024-09-20
NO340925B1 (no) 2017-07-17
NO2018002I1 (no) 2018-01-11
BRPI0413276B1 (pt) 2020-03-03
EP1660531A2 (en) 2006-05-31
KR20060132543A (ko) 2006-12-21
BRPI0413276A (pt) 2006-10-10
KR101159559B1 (ko) 2012-06-26
CY2013029PI2 (el) 2015-11-04
LU92226I9 (OSRAM) 2018-11-19
NO2018003I1 (no) 2018-01-11
NO2024004I1 (no) 2024-01-16
WO2005012347A2 (en) 2005-02-10
US20060183668A1 (en) 2006-08-17
CA2531988A1 (en) 2005-02-10
RU2518460C2 (ru) 2014-06-10
AU2004261353A1 (en) 2005-02-10
BRPI0413276B8 (pt) 2021-05-25
EP2107069A3 (en) 2009-11-25
WO2005012347A3 (en) 2005-04-14
FR13C0035I2 (fr) 2014-03-07
CY2013029I2 (el) 2024-09-20
LU92213I9 (OSRAM) 2018-11-19
EP2264065A3 (en) 2011-07-27
EP2107069A2 (en) 2009-10-07
FR13C0038I1 (fr) 2013-08-09
CY2013029I1 (OSRAM) 2024-09-20
IL172980A (en) 2013-10-31
LU92213I2 (fr) 2013-08-23
EP2264065A2 (en) 2010-12-22
RU2008152033A (ru) 2010-07-10
JP2007523881A (ja) 2007-08-23
AU2004261353B2 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
HUS1300033I1 (hu) Új inzulin származékok
IL169905A0 (en) Novel 2-pyridinecarboxamide derivatives
IL174154A0 (en) Novel glp-1 derivatives
SI2107069T1 (sl) Novi inzulinski derivati
PL1694385T3 (pl) Zestaw do infuzji
SI1594840T1 (sl) Derivati piperidin-benzensulfonamida
GB0317665D0 (en) Qinazoline derivatives
PL1682493T3 (pl) Pochodne amidoacetonitrylu
PL1606277T3 (pl) Pochodne imidazol-4-iloetynylo-pirydyny
TWI368482B (en) New 2-pyridinylethylbenzamide derivatives
AU2003259457A8 (en) Auto-destructible syringe
IL176562A0 (en) Amidopyrazole derivative
IL175189A0 (en) N-thiazol-2-yl-benzamide derivatives
PL1706373T3 (pl) Pochodne amidoacetonitrylu
AP2006003666A0 (en) Syringe
GB0312368D0 (en) Novel ureido- and amido-pyrazolone derivatives
GB2401043B (en) Drug
GB0319793D0 (en) Pyridinylmorpholine derivatives
EP1624073A4 (en) DRUG
TWI341309B (en) Heteroarylcarbamoylbenzene derivatives
AU2003280821A8 (en) Beauveriolide derivative
GB0319148D0 (en) Azaquinazoline derivatives
AU2003280822A8 (en) Beauveriolide derivatives
HU0300481D0 (en) Syringe
GB0318854D0 (en) Self-sterilising syringe